

Supplementary Table 3. Baseline characteristics of GTB patients who received ATT and underwent IVF-ET in the included studies

Characteristic	Bapna et al. [20] (2005)	Caliskan et al. [31] (2014)	Dai et al. [32] (2020)	Dam et al. [33] (2006)	Frydman et al. [34] (1985)	Gupta et al. [35] (2020)	Gurgan et al. [36] (1996)	Jain and Jain [37] (2013)	Jindal [21] (2006)	Jindal et al. [23] (2012)	Jindal and Kumar [38] (2022)	Jirge et al. [12] (2018)	Kharouf et al. [39] (2005)	Kim and Chang [11] (1989)	Kim and Kang [40] (2002)	Lin et al. [10] (2019)	Sharma [41] (2015)	Marcus et al. [42] (1994)	Nayar et al. [43] (2011)	Parikh et al. [44] (1997)	Sharma et al. [29] (2016)	Soussis et al. [45] (1998)	Pooled average (95% CI), I ² (P-value)
Length of study (yr)	2	4	7	1	2	2	NS	3	3	2	4	3	9	NS	7	7		5	1	2	1	9	
Number of patients	49	36	155	58	20	19	24	51	32	32	125	137	15	52	54	113	120	10	78	30	52	13	
Age (yr)	NS	32.0 ±4.1	29.8 ±3.7	NS	30.5 ±5.4	31.2 ±4.2	33.7 ±4.3	NS	NS	NS	NS	NS	34.1 ±5.7	31.6 ±2.9	31.5 ±0.4	30.9 ±4.1	NS	38.5 ±3.2	NS	NS	NS	33.0 ±4.5	
Type of infertility																							
Primary	NS	34 (94.4)	122 (78.7)	NS	14 (70.0)	12 (63.2)	NS	NS	NS	NS	NS	NS	13 (86.7)	NS	NS	107 (94.7)	NS	9 (90.0)	NS	NS	NS	10 (76.9)	83.1 (73.9 to 92.3), 7 (0.367)
Secondary	NS	2 (5.6)	33 (21.3)	NS	6 (30.0)	7 (36.8)	NS	NS	NS	NS	NS	NS	2 (13.3)	NS	NS	6 (5.3)	NS	1 (10.0)	NS	NS	NS	3 (23.1)	14.8 (6.7 to 22.9), 82 (0.00001)
Duration of infertility	NS	NS	4.5 ±3.2	3 to10	NS	6.8 ±3.8	11.2 ±4.6	NS	NS	NS	NS	NS	NS	NS	5.1 ±0.4	6.0 ±1.2	NS	8.8 ±4.5	NS	NS	NS	8.8 ±3.5	
Imaging findings suggestive to FGTB (no. positive / examined)																							
Normal	0/49 (0.0)	0/36 (0.0)	0/155 (0.0) ^b	58/58 (100.0) ^c	0/20 (0.0)	19/19 (100.0)	0/24 (0.0)	0/51 (0.0)	NS	32/32 (100.0) ^c	NS	137/137 (100.0)	0/15 (0.0)	0/52 (0.0)	0/54 (0.0)	0/113 (0.0)	NS	0/10 (0.0)	NS	NS	NS	0/13 (0.0)	7.5 (4.0 to 11.1), 95 (<0.00001)
Tuberculous tubal aetiology ^a	49/49 (100.0)	36/36 (100.0)	130/155 (83.9) ^b	0/58 (0.0) ^c	20/20 (100.0)	0/19 (0.0) ^c	24/24 (100.0)	51/51 (100.0)	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	15/15 (100.0)	52/52 (100.0)	53/54 (98.1)	113/113 (100.0)	NS	10/10 (100.0)	NS	NS	NS	10/13 (76.9)	60.1 (49.3 to 70.9), 98 (<0.00001)
Tubal blockage	NS	36/36 (100.0)	0/155 (0.0) ^b	0/58 (0.0) ^c	15/20 (75.0)	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	48/54 (88.9)	113/113 (100.0)	NS	10/10 (100.0)	NS	NS	NS	7/13 (53.8)	15.3 (9.9 to 20.6), 96 (<0.00001)
Coiled, kinked, beaded tube	NS	15/36 (41.7)	0/155 (0.0) ^b	0/58 (0.0) ^c	NS	0/19 (0.0) ^c	24/24 (100.0)	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	NS	0/113 (0.0)	NS	NS	NS	NS	NS	7/13 (53.8)	15.7 (10.5 to 20.9), 96 (<0.00001)
Hydrosalpinx	NS	12/36 (33.3)	0/155 (0.0) ^b	0/58 (0.0) ^c	NS	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	10/54 (18.5)	0/113 (0.0)	NS	NS	NS	NS	NS	4/13 (30.7)	1.2 (0.0 to 2.6), 69 (0.0010)
Extravasation of fallopian tube	NS	NS	0/155 (0.0) ^b	0/58 (0.0) ^c	NS	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	NS	0/113 (0.0)	NS	NS	NS	NS	NS	NS	0.0
Presence of nodules or tubercles	NS	NS	130/155 (83.9) ^b	0/58 (0.0) ^c	12/20 (60.0)	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	52/52 (100.0)	53/54 (98.1)	NS	NS	NS	NS	NS	NS	10/13 (76.9)	28.6 (19.3 to 37.9), 93 (<0.00001)
Uterine abnormalities (including tuberculous inflammation)	16/49 (32.7)	21/38 (55.3)	25/155 (16.1) ^b	0/58 (0.0) ^c	5/20 (25.0)	0/19 (0.0) ^c	6/24 (25.0)	18/51 (35.3)	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	0/15 (0.0)	NS	26/54 (48.1)	0/113 (0.0)	NS	3/4 (75.0)	NS	NS	NS	3/13 (23.1)	9.2 (5.7 to 12.8), 86 (<0.00001)
Intrauterine synechia	16/49 (32.7)	21/38 (55.35)	0/155 (0.0) ^b	0/58 (0.0) ^c	2/20 (10.0)	0/19 (0.0) ^c	6/24 (25.0)	18/51 (35.3)	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	0/15 (0.0)	NS	17/54 (31.5)	0/113 (0.0)	NS	0/4 (0.0)	NS	NS	NS	1/13 (7.7)	3.9 (0.0 to 6.2), 83 (<0.00001)

Supplementary Table 3. Baseline characteristics of GTB patients who received ATT and underwent IVF-ET in the included studies (Continued)

Characteristic	Bapna et al. [20] (2005)	Caliskan et al. [31] (2014)	Dai et al. [32] (2020)	Dam et al. [33] (2006)	Frydman et al. [34] (1985)	Gupta et al. [35] (2020)	Gurgan et al. [36] (1996)	Jain and Jain [37] (2013)	Jindal [21] (2006)	Jindal et al. [23] (2012)	Jindal and Kumar [38] (2022)	Jirge et al. [12] (2018)	Kharouf et al. [39] (2005)	Kim and Chang [11] (1989)	Kim and Kang [40] (2002)	Lin et al. [10] (2019)	Sharma [41] (2015)	Marcus et al. [42] (1994)	Nayar et al. [43] (2011)	Parikh et al. [44] (1997)	Sharma et al. [29] (2016)	Soussis et al. [45] (1998)	Pooled average (95% CI), I ² (P-value)		
Endometrial atrophy	NS	NS	0/155 (0.0) ^b	0/58 (0.0) ^c	2/20 (10.0)	0/19 (0.0) ^c	0/24 (0.0)	5/51 (9.8)	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	0/15 (0.0)	NS	NS	0/113 (0.0)	NS	3/4 (75.0)	NS	NS	NS	NS	0.5 (0.0 to 1.1), 11 (0.342)		
Presence of nodules or tubercles or tuberculous inflammation	NS	NS	25/155 (16.1) ^b	0/58 (0.0) ^c	5/20 (25.0)	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	20/52 (38.5)	26/54 (48.1)	0/113 (0.0)	NS	0/10 (0.0)	NS	NS	NS	NS	3/13 (23.1)	5.9 (2.7 to 9.1), 87 (<0.00001)	
Mild to moderate pelvic adhesions	NS	31/36 (86.1)	0/155 (0.0) ^b	0/58 (0.0) ^c	3/20 (15.0)	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	NS	0/113 (0.0)	NS	NS	NS	NS	NS	NS	NS	1.2 (0.0 to 2.9), 74 (<0.00001)	
Frozen pelvis	NS	5/36 (13.9)	0/155 (0.0) ^b	0/58 (0.0) ^c	0/20 (0.0)	0/19 (0.0) ^c	NS	NS	NS	0/32 (0.0) ^c	NS	0/137 (0.0) ^c	NS	NS	NS	0/113 (0.0)	NS	NS	NS	NS	NS	NS	NS	NE	
Surgery for FGTB treatment																									
Yes	NS	21 (58.3)	0 (0.0)	0 (0.0)	20 (100.0)	0 (0.0)	6 (25.0)	18 (35.3)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	54 (100.0)	0 (0.0)	NS	10 (100.0)	NS	NS	NS	NS	1 (7.7)	30.3 (0.0 to 80.3), 90 (<0.00001)	
Tuboplasty	NS	0 (0.0)	0 (0.0)	0 (0.0)	13 (65.0)	0 (0.0)	0 (0.0)	0 (0.0)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	0 (0.0)	NS	NS	NS	NS	NS	NS	NE
Salpingotomy	NS	8 (22.2)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	38 (70.4)	0 (0.0)	NS	6 (60.0)	NS	NS	NS	NS	NS	NS	3.5 (0.7 to 6.4), 85 (<0.00001)
Salpingectomy	NS	13 (36.1)	0 (0.0)	0 (0.0)	8 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	10 (18.5)	0 (0.0)	NS	3 (30.0)	NS	NS	NS	NS	NS	NS	2.0 (0.3 to 3.8), 66 (0.0010)
Salpingo-oophorectomy	NS	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	1 (10.0)	NS	NS	NS	NS	NS	NS	NE
Hysteroscopic adhesiolysis	16 (32.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6 (25.0)	18 (35.3)	NS	0 (0.0)	NS	0 (0.0)	0 (0.0)	NS	17 (31.5)	0 (0.0)	NS	0 (0.0)	NS	NS	NS	NS	1 (7.7)	3.5 (1.3 to 5.7), 76 (<0.00001)	
No	NS	15 (41.7)	155 (100.0)	58 (100.0)	0 (0.0)	19 (100.0)	NS	33 (64.7)	NS	32 (100.0)	NS	137 (100.0)	15 (100.0)	NS	0 (0.0)	113 (100.0)	NS	0 (0.0)	NS	NS	NS	NS	12 (92.3)	67.3 (43.4 to 91.3), 98 (<0.00001)	
Positive diagnosis of TB (+TB/no. of patients tested)																									
Hysterosalpingo-graphy	0/0	36/36 (100.0)	0/0	0/0	9/20 (45.0)	0/19 (0.0)	24/24 (100.0)	NS	NS	0/0	0/0	0/0	0/0	NS	39/43 (90.7)	113/113 (100.0)	NS	0/0	NS	NS	NS	NS	8/13 (61.5)	71.2 (0.0 to 144.8), 96 (<0.00001)	
Laparoscopy	49/49 (100.0)	36/36 (100.0)	155/155 (100.0)	0/0	20/20 (100.0)	0/19 (0.0)	0/0	NS	NS	NS	NS	0/137 (0.0)	15/15 (100.0)	NS	29/30 (96.7)	0/0	NS	0/0	NS	NS	NS	NS	0/0	64.8 (37.4 to 92.2), 98 (<0.00001)	

Supplementary Table 3. Baseline characteristics of GTB patients who received ATT and underwent IVF-ET in the included studies (Continued)

Characteristic	Bapna et al. [20] (2005)	Caliskan et al. [31] (2014)	Dai et al. [32] (2020)	Dam et al. [33] (2006)	Frydman et al. [34] (1985)	Gupta et al. [35] (2020)	Gurgan et al. [36] (1996)	Jain and Jain [37] (2013)	Jindal [21] (2006)	Jindal et al. [23] (2012)	Jindal and Kumar [38] (2022)	Jirje et al. [12] (2018)	Kharouf et al. [39] (2005)	Kim and Chang [11] (1989)	Kim and Kang [40] (2002)	Lin et al. [10] (2019)	Sharma [41] (2015)	Marcus et al. [42] (1994)	Nayar et al. [43] (2011)	Parikh et al. [44] (1997)	Sharma et al. [29] (2016)	Soussis et al. [45] (1998)	Pooled average (95% CI), I ² (P-value)	
Hysteroscopy	16/49 (32.7)	36/36 (100.0)	0/0	0/0	0/0	0/19 (0.0)	0/0	NS	NS	NS	NS	0/0	0/15 (100.0)	NS	19/24 (79.2)	0/0	NS	3/4 (75.0)	NS	NS	NS	0/0	26.1 (11.8 to 40.4), 92 (<0.00001)	
Histopathology	NS	27/36 (75.0)	155/155 (100.0)	21/58 (36.2)	20/20 (100.0)	0/0	24/24 (100.0)	NS	NS	NS	NS	0/0	15/15 (100.0)	52/52 (100.0)	54/54 (100.0)	113/113 (100.0)	NS	10/10 (100.0)	NS	NS	NS	13/13 (100.0)	89.8 (71.2 to 108.5), 79 (<0.00001)	
USG	0/0	0/0	0/0	0/0	0/0	0/0	0/0	NS	NS	0/0	0/0	0/0	0/0	0/0	0/0	0/0	NS	0/0	NS	NS	NS	0/0	0.0	
Culture	0/0	3/36 (8.3)	NS	34/ 58 (41.4)	0/0	0/0	0/0	NS	NS	0/0	NS	0/0	0/0	NS	0/0	0/113 (0.0)	NS	0/0	NS	NS	NS	4/13 (30.8)	21.5 (1.9 to 41.2), 93 (<0.00001)	
PCR	0/0	28/36 (77.8)	0/0	58/58 (100.0)	0/0	19/19 (100.0)	0/0	NS	NS	NS	NS	137/137 (100.0)	0/0	NS	1/5 (20.0)	113/113 (100.0)	NS	0/0	NS	NS	NS	0/0	86.4 (67.4 to 102.2), 69 (0.0007)	
Others (ELISA/ESR/ mantoux)	0/0	0/0	0/0	0/0	0/0	0/0	0/0	NS	NS	NS	0/0	0/0	0/0	NS	0/0	0/0	NS	0/0	NS	NS	NS	0/0	0.0	
History of TB	NS	7 (19.4)	NS	NS	2 (10.0)	3 (15.7)	NS	NS	NS	0 (0.0)	NS	0 (0.0)	NS	NS	NS	13 (11.5)	NS	2 (20.0)	NS	NS	NS	5 (38.5)	4.8 (1.3 to 8.3), 78 (<0.00001)	
ATT durations (months)	6	6 to 12	6 to 12	3	9 to 12	None	6 to 12	NS	6	6	NS	6	6 to 12	NS	NS	6 to 12	NS	9 to 24	NS	NS	6 or 9	18 to 24	3 to 24 months	
ATT drugs	NS	INH+RMP +EMB+PZA 2 months; INH+RMP 4 months to 10 months	INH+RMP +EMB+PZA 2 months; INH+RMP 4 months to 10 months	INH+RMP +EMB+PZA 2 months; INH+RMP 1 month	INH+RMP +EMB+PZA 2 months; INH+RMP 7 to 22 months	Not treated or INH+RMP +EMB+PZA 7 months	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	INH+RMP +EMB+PZA 2 months; INH+RMP 4 months or 7 months	NS	
ATT drugs dose	NS	INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg	NS	INH 600 mg, RMP 450 mg, EMB 800 mg, PZA 1,500 mg	INH 3-10 mg/kg, RMP 10 mg/kg, EMB 15 mg/kg, streptomycin	NS	NS	NS	NS	INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg	NS	

GTB, genital tuberculosis; ATT, antitubercular therapy; IVF-ET, *in vitro* fertilization-embryo transfer; CI, confidence interval; NS, not stated/specified; NE, not estimable; FGTB, female genital tuberculosis; TB, tuberculosis; USG, ultrasound sonography; PCR, polymerase chain reaction; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; ATT, antitubercular therapy; INH, Isoniazid; RMP, rifampicin; EMB, ethambutol; PZA, pyrazinamide; HSG, hysterosalpingography.

^aIncluding definitive (multiple granuloma, exudates, loculated fluid, adhesion, hydrosalpinges, and beaded tubes) and probable (signs of chronic inflammation, patent tubes with congestion, small scattered granulomas, fimbrial agglutination and phimosis, tubal sacculatation, mild adhesion, fluid in pouch of Douglas) diagnosis.

^bPatients were diagnosed positive based on presence of histopathological examination of endometrial or tubal biopsy and tuberculous nodules on laparoscopy. However, before the start of oocyte retrieval cycles, they were confirmed to have normal ESR, chest X-ray, pelvic USG, HSG, and hysteroscopy.

^cLatent or subclinical tuberculosis; no evidence of tubal or endometrial damage while the PCR tests, cultures, or smears were positive for mycobacterium tuberculosis.